Abstract
Primary hepatic lymphoma (PHL) is a tumor confined to the liver without involvement of the spleen, lymph nodes, or bone marrow. It is an extremely rare malignancy, accounting for only 0.0016% of non-Hodgkin lymphoma worldwide. Generally, a liver biopsy is required to make a diagnosis of PHL due to the lack of specific clinical manifestations, biochemical indicators, and image features. However, there is currently a lack of consensus on the standard treatment of PHL. Chemotherapy can be an effective treatment due to the tumor's chemosensitivity. Herein, we report a 78-year-old male with a confirmed diagnosis of primary hepatic diffuse large B-cell lymphoma via liver biopsy. We treated the patient with immunochemotherapy using Rituximab-COP combination. The tumor had a favorable response, without recurrence for over a three-year period of follow-up. Even though the reported median survival of PHL is 15 months, appropriate treatment can provide a chance for sustained remission.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
